SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Biotech Valuation
CRSP 55.26+1.2%Nov 11 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
From: Ian@SI5/20/2006 9:20:08 PM
   of 52153
 
From Barron's

The Leaders in Follow-on Biotech

The relatively few contenders in the market for follow-on biologics, or biosimilars, will allow higher prices and profits than the traditional generic business. Novartis and Teva have big ambitions.

	                Recent
Company/Ticker   	Price 	Comment
Novartis / NVS 	       $56.81 	Sandoz unit is world's No. 2 generic maker.
Teva Pharma / TEVA 	37.25 	Top generic firm, sells biogenerics in developing nations.
Barr Pharma / BRL 	50.65 	Feisty litigator, its Duramed unit is targeting biogenerics.
Shire / SHPGY 	        45.75 	Plans 2007 European launch of erythropoeitin.
Stada / SAZ GR 	       €34.89 	German generic leader, plans European erythropoietin in '07.
Wockhardt / WPL IN 	404.45* 	Indian firm sells insulin and erythropoietin in Russia.
Pliva / PLVARA CZ 	575** 	Developing G-CSF with Australia's Mayne Pharma.
 

*Indian Rupees **Croatian Kuna
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News